Skip to main content
. 2023 Apr 27;7(5):709–722. doi: 10.1007/s41669-023-00415-0

Table 2.

Study design and baseline characteristics of studies reporting humanistic impact of immunoglobulin A nephropathy

Author (year) Study design Country Year range for data collection Measures reported Inclusion criteria Study population and patient characteristics
Marsh et al. (2021) [18] Patient preference elicitation study USA and China NR An interview-based swing weighting approach to assess patient preference elicitation To be eligible, participants had to be ≥ 18 years of age at the time of consent, self-report having biopsy-verified primary IgAN, currently receiving ACEi/ARBs for at least 6 months, and be fluent in English (in the USA) or Mandarin (in China)

Population

USA, n = 25; China, n = 15

Mean age:

41.6 years

Race/ethnicity (US population):

68% Caucasian; 16% Latino; 12% Black/African American; 4% Asian

Sex:

32.5% male; 67.5% female

Mizerska-Wasiak et al. (2021) [19] Multicenter cross-sectional study Poland 2000–2015

Kidscreen-52 questionnaire

The Anger Expression Scale

The Personal Competence (KompOs) Scale

Patient age ≥ 8 years, no disease exacerbation during the last 3 months, and written informed consent for study participation

Population:

n = 51

Mean age:

15.5 years

Mean duration of IgAN:

5 years

Patients with hematuria/proteinuria:

76.5%

Zhao et al. (2020) [20] Prospective observational China 2013–2018

The Beck Depression Inventory-II (BDI-II)

Eysenck Personality Questionnaire (EPQ)

Quality of Life Index (QLI)

Life Satisfaction Index (LSI)

Short Form-36 (SF-36)

(1) Adults (age > 18 years); (2) patients who were diagnosed with IgAN on renal biopsy; and (3) Beck Depression Inventory-II (BDI-II) score > 14

Population:

Physical activity (PA), n = 108; no intervention (NI) n = 108

Mean age:

PA: 56.1 years; NI: 58.1 years

Sex:

PA: 62% female; NI: 58.3% female

Receiving dialysis:

PA: 35.2%; NI: 38.9%

NR not reported, ACEi/ARBs angiotensin-converting enzyme inhibitors/ angiotensin receptor blockers, GN glomerulonephritis, BC British Columbia, HRU healthcare resource use, ESKD end-stage kidney disease